85300-32-9

Upstream product

• 108-46-3 recorcinol 
• 100-39-0 benzyl bromide 
• 3769-41-3 3-Benzyloxyphenol 
• 748798-75-6 N-{2-[3-(benzyloxy)phenoxy]ethyl}acetamide 

Downstream Products

• 748798-77-8 2-(2-hydroxyethyl)-N-[2-(3-benzyloxyphenoxy)ethyl]benzamide 
• 748798-78-9 2-{2-[({2-[2-(benzyloxy)phenoxy]ethyl}amino)carbonyl]phenyl}ethyl ethyl carbonate 
• 1026745-37-8 11-benzyloxy-5,7,8,13b-tetrahydro-6H-9-oxa-6a-aza-benzo[6,7]cyclohepta[1,2-a]naphthalene 

Relevant academic research and scientific papers

ALKOXY COMPOUNDS FOR DISEASE TREATMENT

The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are alkoxyl derivative compounds and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.

Dopamine/serotonin receptor ligands. 9.1 oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 receptor selectivity

Eleven-membered heterocycles (dibenz[g,j]-1-oxa-4-azacycloundecenes) and open-chain analogues were synthesized and investigated for affinities to human dopamine receptor subtypes. The moderately rigidized rings displayed nanomolar and subnanomolar Ki values at D1-like receptors with a significant D1 to D2 and a slight D5 to D 1 selectivity. The open-chain analogues showed lower affinities but significant D1 to D2 selectivities. Compound 3 (K i(D5) = 0.57 nmol) showed antagonistic or inverse agonistic binding characteristics in a functional Ca assay.